Tag Archives: Elinzanetant
08
Dec
Comparing Elinzanetant with Current Options for VMS and Sleep Management
This episode notes that elinzanetant offers a targeted, non-hormonal option for women seeking relief...
21
Nov
Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Menopause
This educational roundtable convenes leaders in women’s health to discuss the pathophysiology and qu...
21
Nov
Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Women with Breast Cancer Receiving Endocrine Therapy
This educational roundtable convenes leaders in women’s health to discuss the pathophysiology and qu...
24
Oct
Elinzanetant demonstrates favorable safety profile in menopausal women, with James A. Simon, MD
TakeawaysElinzanetant demonstrated a favorable safety profile over one year in menopausal women with...
24
Oct
FDA approves elinzanetant (Lynkuet) for vasomotor menopausal symptoms
The FDA has approved elinzanetant 60 mg capsules (Lynkuet; Bayer) for the treatment of moderate to s...
28
Sep
JoAnn Pinkerton, MD, highlights long-term safety and efficacy of elinzanetant
The recently published 52-week OASIS-3 trial evaluated the safety and efficacy of elinzanetant, a no...
23
Sep
OASIS-3 highlights safety and efficacy of elinzanetant against VMS
OASIS-3 highlights safety and efficacy of elinzanetant against VMS | Image Credit: © Rido - © Rido -...
11
Aug
Weight and Muscle Mass Outcomes With Elinzanetant
Video content above is prompted by the following: The OASIS-3 subanalysis revealed favorable body co...
11
Aug
BMD Biomarker Outcomes With Elinzanetant vs Placebo: Clinical Relevance and Implications
Video content above is prompted by the following: The OASIS-3 bone mineral density (BMD) subanalysis...
25
Jul
FDA extends review period for Bayer’s elinzanetant for vasomotor symptoms
FDA extends review period for Bayer's elinzanetant for vasomotor symptoms | Image credit: Contempora...